- Shares of Tesaro (TSRO +7%) are getting a boost from an upgrade by BMO Capital to Outperform from Perform along with a $10 PT hike to $46.
- The firm cites meetings with management, from which it came away seeing "a significant opportunity [...] for rolapitant within NCCN treatment guidelines" to the tune of peak sales of $400M.
- Additional upside could come from "large contracts on rolapitant approval, IV development, and pipeline progress, particularly with PARP inhibitor niraparib."
Tesaro +7%, BMO sees "significant opportunity" for rolapitant
Jan 21 2014, 10:30 ET